Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.
Unresectable|Locally Advanced or Metastatic Solid Tumors
DRUG: IBI3005
Numbers of subjects with adverse events, defined as any untoward medical occurrence, whether or not there is a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed, Up to 3 years|Number of subjects with clinically significant changes in physical examination results, Clinically significant abnormal physical examination findings reported by the investigator., Up to 3 years|Number of subjects with clinically significant changes in vital signs, Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure, Up to 3 years|Dose limiting toxicities (DLTs), Dose limiting toxicities (DLTs) to establish MTD and/or RP2D., Up to 4 weeks
area under the curve (AUC), area under the curve (AUC) of single and multiple doses of IBI3005, up to 3 years|maximum concentration (Cmax), maximum concentration (Cmax) of single and multiple doses of IBI3005, up to 3 years|time to maximum concentration (Tmax), time to maximum concentration (Tmax) of single and multiple doses of IBI3005, up to 3 years|clearance (CL), clearance (CL) of single and multiple doses of IBI3005, up to 3 years|apparent volume of distribution (V), apparent volume of distribution (V) of single and multiple doses of IBI3005, up to 3 years|half-life (t1/2), half-life (t1/2) of IBI3005 to the last administration of IBI3005, up to 3 years|anti-drug antibody (ADA), Incidence and characterization of anti-drug antibody (ADA)., up to 3 years|objective response rate (ORR), objective response rate (ORR) as evaluated per the RECIST v1.1 criteria., up to 3 years|duration of response (DoR), duration of response (DoR) as evaluated per the RECIST v1.1 criteria., up to 3 years|time to response (TTR), time to response (TTR) as evaluated per the RECIST v1.1 criteria., up to 3 years|progression free survival (PFS), as evaluated per the RECIST v1.1 criteria., up to 3 years
The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.